drugset / Trial / NCT01543464
Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to assess if treatment with IDO/Survivin peptide vaccine can enhance the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.
Timeline
- Start
- 2012-05
- Primary completion
- 2016-09
- Completion
- 2016-09
Outcome
Outcome not reported
Stopped: “Diminished rectruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDO5 peptide | Vaccine | 250 ug | — |
| Subject | Survivin peptide | Peptide | 250 ug | — |
| Background | GM-CSF | Protein / enzyme biologic | 75 ug | — |
| Background | Imiquimod | Other / unclassified | — | — |
| Background | Montanide | Other / unclassified | 0.5 ml | — |
| Background | Temozolomide | Small molecule | — | — |